Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
7.625 USD -0.07 ( 0.85%)
Last update at 2026-11-09T17:55:00Z
VOLUME
1130017
Market Cap
2304.86M
P/E
7.59

Momentum Score

…

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.54
Low
7.78
High
52 Week Price Range
6.00
Low
11.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioCryst Pharmaceuticals is a commercial-stage biopharma focused on oral small-molecule therapies for rare diseases; its marketed product Orladeyo (berotralstat) provides oral prophylaxis for hereditary angioedema and the company is advancing oral complement inhibitors such as BCX9930. Long-term growth drivers include greater Orladeyo adoption, potential label or indication expansions, pipeline clinical progress and the broader market opportunity for oral complement therapies, which may benefit investors seeking exposure to specialty therapeutics.

Material risks include clinical and regulatory setbacks, competition from established injectable HAE treatments and other complement inhibitors, reliance on a single marketed product for revenue and potential financing needs to advance development.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.69
Dividend Yield
-
Revenue TTM
874.84M
Revenue Per Share
4.17
Gross Profit TTM
691.68M
Debt / Equity
-4.01
ROE
-1925.37%
Net Debt
387.59M
ROCE
108.86%
Diluted EPS TTM
1.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 267.39M -86.95M -226.23M -244.38M -181.81M
Net income 263.86M -88.88M -226.54M -247.12M -184.06M
Selling general administrative 348.65M 252.50M 199.14M 159.37M 118.82M
Selling and marketing expenses - 13.57M 14.40M - -
Gross profit 855.76M 438.23M 326.75M 264.23M 149.91M
Reconciled depreciation 1.39M 1.25M 1.63M 1.44M 0.78M
Ebit 346.26M 11.56M -117.99M -148.44M -177.72M
Ebitda 347.65M 12.81M -116.33M -143.31M -177.66M
Depreciation and amortization 1.39M 1.25M 1.66M 5.13M 0.06M
Non operating income net other - - - - 55.14M
Operating income 340.99M -2.54M -103.71M -148.44M -177.72M
Other operating expenses 533.85M 453.25M 435.12M 419.26M 334.89M
Interest expense 78.87M 98.52M 108.24M 99.09M 59.29M
Tax provision 3.53M 1.93M 1.82M 2.73M 2.25M
Interest income 10.67M 14.75M 14.02M 5.13M 0.06M
Net interest income -68.20M -83.77M -96.10M -93.97M -59.23M
Income tax expense 3.53M 1.93M 0.31M 2.73M 2.25M
Total revenue 874.84M 450.71M 331.41M 270.83M 157.17M
Total operating expenses 514.77M 440.77M 430.46M 412.67M 327.63M
Cost of revenue 19.07M 12.48M 4.66M 6.59M 7.26M
Total other income expense net -73.60M -84.41M -122.52M -95.95M -4.09M
Net income from continuing ops 263.86M -88.88M -236.35M -247.12M -184.06M
Net income applicable to common shares - - - -247.12M -184.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 514.16M 490.42M 516.96M 550.00M 588.15M
Other current assets 17.38M 13.75M 19.54M 12.59M 9.99M
Total liab 633.31M 966.35M 972.49M 844.60M 695.14M
Total stockholder equity -119.15M -475.93M -455.53M -1454.62M -1207.50M
Other current liab 140.16M 113.29M 102.88M 87.56M 72.67M
Common stock 2.13M 2.08M 2.06M 1.88M 1.84M
Capital stock 2.13M 2.08M 2.06M 1.88M 1.84M
Retained earnings -1506.18M -1770.04M -1681.16M -1454.62M -1207.50M
Other assets - - - 550.00M 588.15M
Cash 89.74M 104.92M 112.45M 304.77M 504.39M
Total current liabilities 196.07M 160.38M 149.99M 105.51M 103.72M
Current deferred revenue - - - 1.22M 1.42M
Net debt 387.59M 736.50M 736.27M 436.69M 88.85M
Short term debt 40.08M 35.45M 26.21M 2.37M 1.82M
Short long term debt total 477.33M 841.42M 848.71M 741.45M 593.24M
Other stockholder equity 1384.86M 1291.10M 1222.24M -1.91M -2.02M
Property plant equipment - - - 15.42M 15.19M
Total current assets 404.35M 421.97M 495.97M 516.50M 566.14M
Long term investments 61.16M 20.32M 0.00M 18.08M 6.83M
Net tangible assets - - - -294.60M -147.04M
Short term investments 185.01M 216.14M 278.34M 119.54M 3.21M
Net receivables 106.82M 79.07M 56.95M 50.60M 29.41M
Long term debt 427.23M 795.92M 811.26M 733.28M 585.46M
Inventory 5.40M 8.09M 28.68M 27.53M 15.79M
Accounts payable 15.83M 11.64M 20.89M 14.36M 27.81M
Accumulated other comprehensive income 0.04M 0.92M 1.34M 0.03M 0.18M
Common stock total equity - - - - 1.84M
Retained earnings total equity - - - - -1207.50M
Non currrent assets other 29.66M 26.94M 12.03M 6.81M 6.47M
Non current assets total 109.81M 68.45M 20.99M 33.50M 22.02M
Capital lease obligations 11.64M 12.82M 13.88M 8.17M 7.78M
Long term debt total - - - - 136.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -5.59M 52.59M -25.81M -128.24M 18.19M
Change to liabilities - - - -22.47M 40.70M
Total cashflows from investing activities -13.69M 52.59M -131.50M -128.24M 15.80M
Net borrowings -301.99M -1.70M 58.38M 73.07M 293.87M
Total cash from financing activities -332.44M -5.76M 32.48M 88.03M 359.67M
Change to operating activities - - - -2.58M -2.99M
Net income 263.86M -88.88M -226.54M -247.12M -184.06M
Change in cash -103.32M -6.12M -193.79M -201.50M 233.39M
Begin period cash flow 104.92M 112.45M 306.24M 507.73M 274.35M
End period cash flow 1.60M 106.32M 112.45M 306.24M 507.73M
Total cash from operating activities 329.88M -52.02M -95.14M -161.85M -142.16M
Issuance of capital stock 0.06M 0.03M 0.34M 0.00M 50.00M
Depreciation 1.39M 1.25M 1.66M 1.44M 0.78M
Other cashflows from investing activities 0.55M -1.12M 0.00M - -
Change to inventory -1.64M -4.16M -1.45M -12.42M -8.77M
Change to account receivables -36.81M -22.70M -6.09M -21.47M -23.80M
Sale purchase of stock - - - - 65.79M
Other cashflows from financing activities -8.85M -4.09M -26.24M 73.07M 309.67M
Change to netincome - - - 141.84M 33.00M
Capital expenditures 2.47M 1.12M 2.17M 1.35M 2.38M
Change receivables - - - - -20.82M
Cash flows other operating - - - - 48.33M
Exchange rate changes - - - - 0.07M
Cash and cash equivalents changes - - - - 233.39M
Change in working capital -56.90M -87.28M -32.40M -58.95M 8.12M
Stock based compensation 85.07M 65.41M 55.62M 44.70M 34.64M
Other non cash items 121.53M 57.48M 106.53M 98.07M 54.20M
Free cash flow 327.41M -53.14M -97.31M -163.20M -144.54M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BCRX
BioCryst Pharmaceuticals Inc		 -0.07
0.85%		 7.62 7.59 114.94 2.63 56.59 2.82 7.10
MKKGY
Merck KGaA ADR		 0.43
1.30%		 33.60 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.01
0.07%		 21.04 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

4505 Emperor Boulevard, Durham, NC, United States, 27703

919 859 1302

https://www.biocryst.com

435

Name Title Year Born
Mr. Jon P. Stonehouse CEO, Pres & Exec. Director 1961
Mr. Anthony J. Doyle Sr. VP & CFO 1980
Dr. William P. Sheridan MBBS Chief Devel. Officer 1955
Dr. Yarlagadda S. Babu Chief Discovery Officer 1953
Dr. Helen M. Thackray FAAP, M.D. Chief R&D Officer 1968
Mr. Michael L. Jones Exec. Director of Fin. & Principal Accounting Officer 1970
Ms. Alane P. Barnes Sr. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John D. Bluth Chief Communications Officer 1973
Ms. Stephanie Angelini Chief People Officer NA
Dr. Elliott T. Berger Sr. VP of Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +4.22%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.64%

  • Healthcare

    +1.58%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…